COTEMPLA XR-ODT

Peak

methylphenidate

NDAORALTABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE
Approved
Jun 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20

Mechanism of Action

(CNS) stimulant. The mode of therapeutic action in ADHD is not known.

Pharmacologic Class:

Central Nervous System Stimulant

Clinical Trials (5)

NCT05669170Phase 2Not Yet Recruiting

Methylphenidate for Apathy in Veterans With Parkinson's Disease

Started Jan 2024
60 enrolled
Parkinson DiseaseApathy
NCT04132557N/ACompleted

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Started Oct 2019
430,000 enrolled
Attention Deficit Disorder With Hyperactivity
NCT03536390Phase 4Withdrawn

A 6-week Study to Evaluate the Safety and Efficacy of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD

Started Sep 2018
0
Attention Deficit Hyperactivity Disorder
NCT02730572N/ACompleted

Concerta (Methylphenidate) -To-Generic Switch Study

Started Sep 2015
1,464 enrolled
Attention Deficit Disorder With Hyperactivity
NCT02315651N/AUnknown

Efficacy of Combined Treatment With CoQ10 and Methylphenidate in Children With Attention Deficit Hyperactivity Disorder

Started Jan 2015
60 enrolled
Attention Deficit Hyperactivity Disorder

Loss of Exclusivity

LOE Date
Jan 25, 2038
144 months away
Patent Expiry
Jan 25, 2038

Patent Records (4)

Patent #ExpiryTypeUse Code
8840924
Jun 5, 2026
Product
9072680
Jun 28, 2032
Product
9089496
Jun 28, 2032
Product
11166947
Jan 25, 2038
U-3299